The American journal of managed care
-
This study evaluated the uptake and costs of 3 biosimilars among Medicare and Medicaid populations for 2019 to 2022: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni). ⋯ Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US.
-
The Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) program is an innovative, patient-centered system of care developed by the University Hospitals Harrington Heart and Vascular Institute in Cleveland, Ohio in the US for the management of high-risk patients with type 2 diabetes (T2D) and prediabetes at high risk for cardiovascular-kidney-metabolic (CKM) syndrome and its consequences. At its core, CINEMA is a multidisciplinary team of care experts, working together outside of traditional silos. The patient meets with the entire team up to 4 times each year to address all aspects of cardiovascular (CV) and T2D care. ⋯ The multiyear results of the CINEMA program indicate that a multidisciplinary approach to management of high-risk patients is highly effective in reducing CKM syndrome risk factors and increases use of guideline-directed therapies. The aim of this review is to describe the structure, operation, and eligibility criteria for admission to the CINEMA program, provide an overview of how CKM syndrome risks are determined and managed for each patient, and discuss how the integrated approach to care is supported by current recommendations from professional societies and results from other coordinated care/multidisciplinary programs. Lastly, the scalability challenges of a wider rollout of the CINEMA program are considered.
-
This commentary, part of the Price Crisis campaign, calls for state and federal policy interventions that are needed to rebalance the market to enhance competition and provide value in health care.
-
Neither care delivery nor public health systems have grappled with widening disparities as life expectancy gaps increase in the US. Reimagining health care and public health requires aligned incentives including attention to vulnerable populations, financial incentives to improve total population health, effective deployment of community assets, and adoption of a continuous learning system. We argue that Big Hairy Audacious Goals-targets for a Health GDP (similar to the economy's gross domestic product [GDP]), Life Expectancy, Safe and Sound Children, One Earth Policy, Social Spending, and Political Healing-can focus our attention and propel needed action.